Fluorine F18-EF5 and Fludeoxyglucose F18 Positron Emission Tomography in Assessing Hypoxia and Glycolysis in Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | May 2009 |
| End Date: | May 2013 |
Assessing Hypoxia by 18F-EF5 PET Scanning and Glycolysis by 18FFDG PET Scanning in Subjects With Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography, using the drug
fluorine F18-EF5 to find oxygen and fludeoxyglucose F18 to find sugar in tumor cells may
help in planning treatment for patients with non-small cell lung cancer.
PURPOSE: This clinical trial is studying fluorine F18-EF5 and fludeoxyglucose F18 positron
emission tomography in assessing hypoxia and glycolysis in patients with stage I, stage II,
or stage III non-small cell lung cancer.Detailed DescriptionOBJECTIVES:
I. To determine whether there is an association between Akt activation and hypoxia as
determine by 18F-EF5 PET scanning in patients with NSCLC.
II. To determine whether there is an association between Akt activation and increased
glycolysis as determined by 18F-FDG PET imaging in patients with NSCLC.
OUTLINE: Within 6 weeks prior to surgery, patients undergo fluorine F18 (18F)-EF5 PET at 10
minutes and 90 minutes after injection of 18F-EF5. Patients also undergo fludeoxyglucose F18
(18F-FDG) PET at 1 hour and 3 hours after injection of 18FFDG.
After completion of study treatment, patients are followed periodically for 5 years.
We found this trial at
1
site
Click here to add this to my saved trials
